A pharmaceutical composition, its preparation method and application
By combining dialkylcysteine dipeptides and silicon-based lipid derivatives, a stable drug composition is formed, which solves the problems of drug stability and release in the gastrointestinal tract, realizes targeted delivery and rapid release of drugs, and improves drug utilization and therapeutic effect.
Patent Information
- Application Number
- CN202310838772.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-10
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-07-10
AI Technical Summary
Existing drug compositions have poor stability in the gastrointestinal tract, leading to drug leakage, making it difficult to achieve on-demand release, reducing drug utilization and increasing toxic side effects.
The combination of dialkylcysteine dipeptide and silicon-based lipid derivatives forms a disulfide bond network structure and an inorganic silicate network structure, ensuring drug stability under strong acid conditions and enabling targeted delivery and rapid release.
It improves the efficiency of drug release within cells, enhances drug targeting, reduces toxic side effects, and improves drug utilization and therapeutic efficacy.
Smart Images

Figure CN116726185B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of chemistry and drug delivery technology, specifically relating to a pharmaceutical composition, its preparation method, and its application. Background Technology
[0002] Oral administration offers convenience, flexibility, and good patient compliance. However, oral drugs need to overcome a wide pH range in the gastrointestinal tract to be absorbed and reach their target. Small molecule drugs (such as gemcitabine) lack targeting specificity, making it difficult to identify their target during oral administration, reducing drug utilization and increasing the risk of toxic side effects, thus hindering their clinical application. Liposomes, due to their high safety and good drug protection, have seen many products enter clinical use. However, while encapsulating drugs in liposomes can enhance efficacy and reduce toxicity, liposomes have poor stability in the gastrointestinal tract, making them prone to leakage. Building on this, scientists have recently developed silica-based liposomes, which can better resist harsh external environments such as strong acids, strong bases, and multiple enzymes, thereby protecting the carried active ingredients.
[0003] CN1416334A relates to a lipid carrier composition for controlled release of bioactive substances, the composition comprising at least one triglyceride oil, and at least one polar lipid selected from phosphatidylethanolamine and hexosylceramide, as well as ethanol; characterized in that the carrier composition has the ability to form an adhesive structure that can be maintained in an aqueous environment, and also relates to a pharmaceutical composition comprising the lipid carrier and a bioactive substance dissolved or dispersed in the carrier; CN1947702A provides a lipid carrier and a method for manufacturing the same. The lipid carrier comprises a lipid microparticle composed of a positively charged lipid, a cholesterol, a neutral phospholipid, and a neutral lipid, wherein the positively charged lipid is approximately 100 parts by weight, the cholesterol is approximately 25-100 parts by weight, the neutral phospholipid is approximately 25-100 parts by weight, and the neutral lipid is approximately 25-150 parts by weight. The lipid carrier has a uniform particle size, high coverage, and high serum stability, and also possesses acid-base sensitivity; however, its dense structure also hinders drug release, making it difficult to achieve on-demand drug release.
[0004] Therefore, in this field, there is a desire to develop a drug composition that can both ensure the drug remains stable and leak-free in the gastrointestinal tract and achieve rapid release at the target site. Summary of the Invention
[0005] To address the shortcomings of existing technologies, the present invention aims to provide a pharmaceutical composition in which a silicon-based lipid derivative can be hydrolyzed and condensed to form an inorganic silicate network structure distributed on the surface of the nanomedicine, and a dialkylcysteine dipeptide can form a disulfide bond network structure on the surface of the nanomedicine, which can remain stable under strong acid conditions, thereby achieving targeted delivery of oral drugs, enabling rapid intracellular drug release and improving efficacy.
[0006] To achieve this objective, the present invention adopts the following technical solution:
[0007] In a first aspect, the present invention provides a pharmaceutical composition comprising a carrier and a drug loaded on the carrier, the carrier comprising a combination of a dialkylcysteine dipeptide and a lipid, the lipid comprising a silicon-complexed lipid derivative, the dialkylcysteine dipeptide having a structure as shown in Formula 1:
[0008]
[0009] Wherein, R1 is a C2-C5 straight-chain or branched alkylene, for example, it can be a C2 straight-chain alkylene, a C3 straight-chain alkylene, a C4 straight-chain alkylene, a C5 straight-chain alkylene, a C2 branched alkylene, a C3 branched alkylene, a C4 branched alkylene, or a C5 branched alkylene.
[0010] R2 and R3 are each independently C12-C24 straight-chain or branched alkyl groups, for example, they can be C12 straight-chain alkylene, C14 straight-chain alkylene, C16 straight-chain alkylene, C18 straight-chain alkylene, C20 straight-chain alkylene, C22 straight-chain alkylene, C24 straight-chain alkylene, C12 branched alkylene, C13 branched alkylene, C15 branched alkylene, C16 branched alkylene, C18 branched alkylene, C20 branched alkylene, C22 branched alkylene, and C24 branched alkylene.
[0011] The pharmaceutical composition provided by this invention includes a carrier comprising a combination of dialkylcysteine dipeptide and lipids, wherein the lipids comprise silicon-based lipid derivatives. On one hand, the dialkylcysteine dipeptide can form a disulfide bond network structure on the surface of the nanomedicine; on the other hand, the silicon-based lipid derivatives can hydrolyze and condense to form an inorganic silicate network structure distributed on the surface of the nanomedicine. This allows the pharmaceutical composition to remain stable under strong acid conditions, enabling targeted delivery of oral drugs, rapid intracellular release of drugs, and improved efficacy.
[0012] The preparation method of the dialkylcysteine dipeptide includes:
[0013] (1) In organic solvents, amine compounds With haloalkanes The mixture was mixed, the pH of the reaction solution was adjusted with sodium carbonate, and after separation and purification, the dialkylimine shown in Formula 2 was obtained.
[0014]
[0015] (2) In organic solvents, acid anhydrides are... After separation and purification, the dialkylimine shown in Formula 2 is used to obtain the dialkylacyl acid shown in Formula 3;
[0016]
[0017] (3) In an organic solvent, the carboxyl group of the dialkyl acyl acid obtained in the previous step is activated using a carbodiimide condensing agent and an active acylation activator. After removing impurities, the activated product is obtained. Subsequently, the activated product is mixed with a cysteine dipeptide, and after separation and purification, a dialkyl cysteine dipeptide is obtained.
[0018] Preferably, the dialkylcysteine dipeptide has the structure shown in Formula 1-1 (dipalmitoylcysteine dipeptide, DPCD):
[0019]
[0020] The preparation method of the dipalmitoylcysteine dipeptide (DPCD) shown in Formula 1-1 is as follows:
[0021] (1) In an organic solvent, palmitamine and 1-bromopalmitane are mixed, the pH of the reaction solution is adjusted with sodium carbonate, and after separation and purification, dipalmitine as shown in Formula 2-1 is obtained.
[0022]
[0023] (2) In an organic solvent, succinic anhydride is mixed with the dipalmitoylimine shown in Formula 2-1, and after separation and purification, dipalmitoylbutyric acid shown in Formula 2-2 is obtained;
[0024]
[0025] (3) In an organic solvent, the carboxyl group of dipalmitoylbutyric acid obtained in the previous step is activated using a carbodiimide condensing agent and an acylation activator. After removing impurities, the activated product is obtained. The activated product is then mixed with a cysteine dipeptide, and after separation and purification, dipalmitoylcysteine dipeptide (DPCD) is obtained.
[0026] Preferably, the lipid further includes phospholipid polyethylene glycol.
[0027] Preferably, the silicon-containing composite lipid derivative includes N-[N-(3-triethoxysilane)-propylsuccinic acid]bis(hexadecylamine). Prepared according to the method reported in the literature ("Stabilized Magnetic Cerasomes for Drug Delivery." Cao, Z.; Yue, X.; Li, X.; Dai, Z., Langmuir 2013, 29, 14976-14983.).
[0028] Preferably, the molar ratio of the phospholipid polyethylene glycol and the dialkylcysteine dipeptide is 1:(5-14), for example, it can be 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0029] Preferably, the molar ratio of the phospholipid polyethylene glycol and the silicon-based lipid derivative is 1:(5-14), for example, it can be 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0030] The pharmaceutical composition of the present invention has a carrier component molar ratio of: phospholipid polyethylene glycol (DSPE-PEG2000): DPCD: silicon complex lipid derivative = 1: (5-14): (14-5).
[0031] Preferably, the drug comprises any one or a combination of at least two of gemcitabine, IR-780 iodide, or fluorescein isothiocyanate.
[0032] Preferably, the mass ratio of the drug to the carrier is 1:(0.05-0.35), for example, it can be 1:0.05, 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0033] In a second aspect, the present invention provides a method for preparing a pharmaceutical composition as described in the first aspect, the method comprising:
[0034] The drug, lipids, and dialkylcysteine dipeptide are mixed to obtain the drug composition.
[0035] Preferably, the preparation method specifically includes: mixing a first solvent, a drug, a silicon-containing complex lipid derivative, phospholipid-methoxy polyethylene glycol and a dialkylcysteine dipeptide, removing the first solvent, adding a second solvent to reconstitute, centrifuging, and adding a third solvent to reconstitute to obtain the drug composition.
[0036] Preferably, the mixing temperature is 10-30℃, for example, it can be 10℃, 15℃, 20℃, 25℃, 30℃, and specific values between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0037] Preferably, the mixing time is 5-30 minutes, for example, it can be 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0038] Preferably, the first solvent includes any one or a combination of at least two of methanol, ethanol, chloroform or ethyl acetate.
[0039] Preferably, the concentration of the drug in the first solvent is 1-2 mg / mL, for example, it can be 1 mg / mL, 1.1 mg / mL, 1.5 mg / mL, 1.8 mg / mL, 2 mg / mL, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0040] Preferably, the second solvent comprises any one or a combination of at least two of water, phosphate buffer, or physiological saline.
[0041] Preferably, the concentration of the drug in the second solvent is 0.01-1 mg / mL, for example, it can be 0.01 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 0.8 mg / mL, 1 mg / mL, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0042] Preferably, the resolution includes any one or a combination of at least two of stirring, vortexing, or sonication.
[0043] Preferably, the third solvent includes any one or a combination of at least two of deionized water, phosphate buffer, or physiological saline.
[0044] Preferably, the concentration of the drug in the third solvent is 0.01-10 mg / mL, for example, it can be 0.01 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 5 mg / mL, 8 mg / mL, 10 mg / mL, and specific values between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values included in the range.
[0045] The preparation process also includes centrifugation, ultraviolet spectroscopy and differential method, or high performance liquid chromatography to quantitatively analyze the active ingredients carried.
[0046] Thirdly, the present invention provides the use of the pharmaceutical composition as described in the first aspect in the preparation of oral pharmaceutical formulations.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] The pharmaceutical composition prepared by this invention can integrate the resistance of silicate network to harsh environments and the responsiveness of disulfide bond network to glutathione. The carrier has the advantages of strong penetration ability, long blood half-life, and significant improvement of the toxicity of small molecule drugs. At the same time, the carrier preparation method is simple, the conditions are mild, the cost is low, and it is easy to promote and apply. Attached Figure Description
[0049] Figure 1 High-resolution electrospray ionization mass spectrum of the dipalmitoylcysteine dipeptide obtained in Example 1;
[0050] Figure 2 This is a stability graph of the pharmaceutical composition in Example 1 under different pH conditions;
[0051] Figure 3 The diagram shows the encapsulation efficiency of the drug by the carrier in Examples 1-3.
[0052] Figure 4 This is a graph showing the drug release behavior of the drug composition in Example 1 under different conditions;
[0053] Figure 5 The figure shows the cell viability test results of the drug composition used in Example 2;
[0054] Figure 6 The figure shows the results of the tumor sphere penetration test using the drug composition in Example 3;
[0055] Figure 7 The figure shows the experimental results of treating tumor spheres using the drug composition in Example 4;
[0056] Figure 8 The figure shows the results of the blood half-life experiment of the drug composition in Example 5;
[0057] Figure 9 Figure 1 shows the results of an animal-level antitumor experiment using the drug composition in Example 6;
[0058] Figure 10 A graph showing the blood urea nitrogen levels of the pharmaceutical composition used in Example 6;
[0059] Figure 11 This is a graph showing the serum creatinine levels of the pharmaceutical composition used in Example 6. Detailed Implementation
[0060] The technical solution of the present invention will be further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as limiting the invention in any way.
[0061] Preparation Example 1
[0062] This preparation example provides a dipalmitoylcysteine dipeptide (DPCD) having the structure shown in Formula 1-1;
[0063]
[0064] The specific preparation method is as follows:
[0065] (1) Synthesis of dipalmitin, the specific preparation method is as follows:
[0066] Palmitamine (24.6 g, 102 mmol) was added to a 100 mL round-bottom flask along with 1-bromopalmitane (34.2 g, 112 mmol) and sodium carbonate (16.6 g, 158 mmol) and 30 mL of ethanol. The mixture was heated to 80 °C and refluxed with ethanol. After the reaction was carried out for one week, the sample was purified by recrystallization with ethanol and impurities were removed by filtration through a quinolone funnel to obtain pure dipalmitinine.
[0067] (2) Synthesis of dipalmitoylbutyric acid, the specific preparation method is as follows:
[0068] Dipalmitoimine (3 g, 6.44 mmol) and succinic anhydride (1.29 g, 12.9 mmol) were added to 50 mL of ultra-dry tetrahydrofuran, heated to dissolve, stirred at room temperature for one day, the solvent was evaporated to dryness, and then dissolved again with dichloromethane. Subsequently, it was extracted with 10% citric acid aqueous solution and saturated sodium chloride aqueous solution. The organic phase was collected, dried with anhydrous magnesium sulfate, and the solvent was removed by rotary evaporation. The crude product was then recrystallized with acetonitrile to give a white solid, which was dipalmitoylbutyric acid.
[0069] (3) Synthesize dipalmitoylcysteine dipeptide. The specific preparation method is as follows:
[0070] Dipalmitoylbutyric acid (1.5 g, 2.7 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) (0.77 g, 4.05 mmol), and N-hydroxysuccinimide (NHS) (0.47 g, 4.05 mmol) were dissolved together in 20 mL of dichloromethane. After stirring at room temperature for 2 h, the byproducts were removed by extraction with deionized water. Subsequently, cysteine dipeptide (0.91 g, 4.05 mmol) was added, and the reaction was carried out for 12 h. After removing the dichloromethane by rotary evaporation, the residue was dissolved in ethyl acetate, allowed to stand for a period of time, filtered to remove the precipitate, and the ethyl acetate was removed by rotary evaporation to obtain a pale yellow oily dipalmitoylcysteine dipeptide (DPCD).
[0071] The dipalmitoylcysteine dipeptide in Preparation Example 1 was detected by high-resolution electrospray ionization mass spectrometry (HR-ESI / MS, Bruker, Solarix 9.4T). Figure 1 As shown, Figure 1 The high-resolution mass spectrometry results showed that the molecular weight of the prepared dipalmitoylcysteine dipeptide was 771.57, which was completely consistent with the theoretical prediction of 771.56, proving the successful preparation of the molecule.
[0072] Example 1
[0073] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0074] (1) Dissolve 1 mg of phospholipid polyethylene glycol (DSPE-PEG2000), silicon complex lipid derivative (preparation method is the same as "Stabilized Magnetic Cerasomes for Drug Delivery." Cao, Z.; Yue, X.; Li, X.; Dai, Z., Langmuir 2013, 29, 14976-14983.), DPCD (molar ratio 1:9.5:9.5) and 0.05 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform, and place them in a round-bottom flask.
[0075] (2) After stirring at 25℃ for 15 minutes, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added, and the film was hydrated by vortexing and sonication.
[0076] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0077] To verify the stability of the pharmaceutical composition prepared in this embodiment under different pH conditions, it was diluted 1:1000 in phosphate buffer solutions with different pH values, and the hydrated particle size distribution at different time points was measured using a dynamic light scattering instrument (Zetasizer NanoZS). The results are as follows: Figure 2 As shown, its particle size can remain unchanged for 24 hours under pH 2 conditions.
[0078] Example 2
[0079] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0080] (1) Dissolve 1 mg of DSPE-PEG2000, silicon complex lipid derivative, DPCD (molar ratio 1:9.5:9.5) and 0.5 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0081] (2) After stirring at 25℃ for 30 min, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added and the film was hydrated by vortexing and sonication.
[0082] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0083] Example 3
[0084] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0085] (1) Dissolve 1 mg of DSPE-PEG2000, silicon complex lipid derivative, DPCD (molar ratio 1:9.5:9.5) and 1 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0086] (2) After stirring at 30℃ for 15 minutes, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added and the film was hydrated by vortexing and sonication.
[0087] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0088] The drug content in the supernatant of Examples 1-3 was obtained by measuring the absorbance at 250 nm using a UV spectrophotometer (Perkin Elmer Lambda 850). The encapsulation efficiency was calculated using the difference method, and the results are as follows: Figure 3As shown, when the drug of the same mass as the carrier is added, the encapsulation efficiency can still exceed 50%, and the drug loading is calculated to be nearly 30%, indicating that the drug composition of the present invention can achieve efficient transport of gemcitabine hydrophobic small molecule drugs.
[0089] Example 4
[0090] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0091] (1) Dissolve 1 mg of phospholipid polyethylene glycol (DSPE-PEG2000), silicon complex lipid derivative, DPCD (molar ratio 1:7:12) and 0.05 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0092] (2) After stirring at 25℃ for 15 minutes, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added, and the film was hydrated by vortexing and sonication.
[0093] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0094] Example 5
[0095] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0096] (1) Dissolve 1 mg of phospholipid polyethylene glycol (DSPE-PEG2000), silicon complex lipid derivative, DPCD (molar ratio 1:14:5) and 0.05 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0097] (2) After stirring at 25℃ for 15 minutes, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added, and the film was hydrated by vortexing and sonication.
[0098] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0099] Example 6
[0100] This embodiment provides a pharmaceutical composition, the specific preparation method of which is as follows:
[0101] (1) Dissolve 1 mg of phospholipid polyethylene glycol (DSPE-PEG2000), silicon complex lipid derivative, DPCD (molar ratio 1:7:12) and 0.05 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0102] (2) After stirring at 25℃ for 30 min, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added and the film was hydrated by vortexing and sonication.
[0103] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine carried, and reconstitute the precipitate with 1 mL of physiological saline to obtain the drug composition.
[0104] Comparative Example 1
[0105] This comparative example provides DPPC liposomes carrying gemcitabine, and the specific preparation method is as follows:
[0106] (1) Dissolve 1 mg of DSPE-PEG2000, DPPC (molar ratio 1:19) and 1 mg of gemcitabine in 0.5 mL of methanol and 1.5 mL of chloroform and place them in a round-bottom flask.
[0107] (2) After stirring at 30℃ for 15 minutes, the solvent was slowly removed by rotary evaporation to form a uniform lipid film. 2 mL of deionized water was added and the film was hydrated by vortexing and sonication.
[0108] (3) Centrifuge at 12000 rpm for 10 minutes, collect the supernatant, measure the absorbance at 250 nm to determine the amount of gemcitabine, and reconstitute the precipitate with 1 mL of physiological saline to obtain the DPPC.
[0109] Application Example 1
[0110] In this application example, the pharmaceutical composition from Example 3 was selected, and its glutathione-responsive drug release capacity was tested. The specific process is as follows:
[0111] 400 μL of the drug composition from Example 3 was added to 1600 μL of phosphate buffer (pH 7.4), and 10 mM GSH was added as a second controlled-release condition. The mixture was incubated in a 37°C water bath. At each measurement time point, 100 μL of sample was aspirated, centrifuged at 8000 rpm for 10 minutes, and the supernatant was collected and added to an enzyme plate. The absorbance at 250 nm was measured to quantify and calculate drug release.
[0112] The release behavior of gemcitabine, the drug carried in this pharmaceutical composition, is as follows: Figure 4As shown, in the presence of glutathione, the drug undergoes rapid release, with a cumulative release exceeding 20% within 2 hours, while in the absence of GSH, this value is only about 6%. This result indicates that the pharmaceutical composition of the present invention possesses glutathione-responsive drug release properties, capable of increasing the rate of drug release in tumors and reducing drug release in normal tissues, thereby reducing toxic side effects.
[0113] Application Example 2
[0114] In this application example, BxPC-3 cells were used as a model, and the CCK-8 assay was used to detect the therapeutic effect of the drug composition. The specific process is as follows:
[0115] Digested BxPC-3 cells were distributed at 1 × 10⁻⁶ cells per well. 4 Cells were evenly seeded at a density in 96-well plates and incubated at 37°C with 5% CO2. After 12 hours, the culture medium was replaced with fresh medium containing different components. The final concentrations of free gemcitabine and the drug composition (from Example 3) were 2, 1.6, 1.2, 0.8, 0.4, and 0.2 mg / mL. After 24 hours, 20 μL of CCK-8 at a concentration of 5 mg / mL was added to each well, and the plates were incubated at 37°C with 5% CO2 for 4 hours. The absorbance of each well was recorded at 450 nm using a microplate reader (PerkinElmer, USA). Five replicates were performed for each concentration, and each experiment was repeated three times.
[0116] The results are as follows Figure 5 As shown in the figure, the therapeutic effect of the drug composition is better than that of free gemcitabine, indicating that the present invention can improve the efficacy of gemcitabine.
[0117] Application Example 3
[0118] In this application example, three-dimensional tumor spheres were constructed using BxPC-3 and HPasTeC cells, and the penetration effect of the drug composition was evaluated. The specific procedures are as follows:
[0119] (1) Using a 48-well plate, 2% (w / v) sterile agarose solution (200 μL) was added to each well, and 5000 BxPC-3 cells and 5000 HPasTeC cells were seeded. The culture conditions were 37℃ and 5% CO2. After 7 days, three-dimensional tumor spheres were successfully prepared.
[0120] (2) Replace the drug in the pharmaceutical composition with FITC, thereby fluorescently labeling it;
[0121] (3) Three-dimensional tumor spheres were added to ultra-low adhesion 24-well plates, and then FITC-labeled drug composition was added to DMEM (1 mg / mL, pH 7.0);
[0122] (4) After 2 hours, the three-dimensional tumor sphere was removed, washed 3 times with phosphate buffer at pH 7.4, and then observed with a laser confocal microscope.
[0123] The results are as follows Figure 6 As shown, the fluorescence can almost penetrate the entire tumor sphere, indicating that the drug composition has strong penetrating power and can improve the therapeutic effect of the drug components it carries.
[0124] Application Example 4
[0125] In this application example, three-dimensional tumor spheres were constructed using BxPC-3 and HPasTeC cells, and the therapeutic effect of the drug composition was evaluated. The specific procedures are as follows:
[0126] (1) The three-dimensional tumor spheroid culture experiment was the same as in Example 6;
[0127] (2) The three-dimensional tumor spheres were transferred to an ultra-low adhesion 24-well plate and free gemcitabine at an equivalent concentration of 1.6 mg / mL, DPPC (from Comparative Example 1), and a drug composition (from Example 3) were added respectively. The control group was added with only an equal volume of PBS.
[0128] (3) After 1, 3 and 7 days, observe the morphology and size of the cell spheres using a microscope;
[0129] The results are as follows Figure 7 As shown, due to increased permeability, the drug composition exhibited stronger therapeutic effects at the three-dimensional tumor sphere level than free gemcitabine and gemcitabine carried by DPPC.
[0130] Application Example 5
[0131] In this application example, using FITC-labeled drug compositions and Balb / c nude mice as a model, the pharmacokinetics of these nanoparticles were evaluated by measuring the FITC content in the blood, thereby determining their blood half-life. The specific procedure is as follows:
[0132] (1) The FITC-labeled drug composition was intravenously injected into tumor-free mice. Tail vein blood samples (0.2 mL) were collected at 0.5, 1, 2, 4, 8, 24, and 48 hours after intravenous injection.
[0133] (2) After collecting the blood into a test tube, immediately centrifuge at 2000 rpm for 15 minutes at 4°C to separate other impurities and plasma;
[0134] (3) Mix 10 μL of plasma with 990 μL of acidified isopropanol. Incubate the resulting mixture overnight at 4°C and store in the dark;
[0135] (4) Centrifuge the sample at 12,000 rpm for 10 minutes, transfer the supernatant to a 96-well plate, and measure the fluorescence using an ELISA reader (λex = 480 nm, λem = 520 nm).
[0136] Concentrations were determined by comparing fluorescence intensity with the FITC standard curve, and the area under the curve (AUC) for each group was calculated. The results are as follows: Figure 8 As shown. The blood half-life of this drug composition can be as long as 13.68 hours, demonstrating its long-term accumulation in tumors and achieving good therapeutic effects.
[0137] Application Example 6
[0138] In this embodiment, the drug composition of Example 3 was used, and Balb / c nude mice were used as a model to verify the in vivo therapeutic effect of the drug composition. The specific operation is as follows:
[0139] Select 5-6 week old female Balb / c nude mice and subcutaneously inject 3×10 mol / L mice into the right hind leg. 6 10 BxPC-3 cells and 3 × 10 6 A tumor model was established using a mixture of HPaSTeC cells. The tumor volume was increased to 100-200 mm². 3 Subsequently, nude mice were randomly divided into three groups of five mice each. Each group received oral PBS, free gemcitabine, or a combination of drugs, with an equivalent gemcitabine dose of 4 mg / kg, administered every two days. The vertical diameter of the tumor was measured daily using calipers to monitor tumor growth. After the experiment, blood was collected intravenously and placed in anticoagulant tubes containing EDTA for the determination of blood urea nitrogen and serum creatinine.
[0140] Tumor volume information Figure 9 As shown, the tumor volume in the control group increased rapidly, while the tumor volume in the free gemcitabine group increased slightly more slowly compared to the control group. Tumor growth in the DPPC group was effectively inhibited, and the tumor volume in the drug composition group was not only inhibited but also smaller than that at the time of initial administration. These results fully demonstrate that the drug composition of the present invention can greatly improve the therapeutic effect of the chemotherapy drug gemcitabine and is superior to gemcitabine carried by conventional DPPC liposomes.
[0141] Blood urea nitrogen and serum creatinine measurement results are as follows Figure 10 and Figure 11 As shown, the pharmaceutical composition of the present invention can greatly reduce the damage to kidney function caused by free gemcitabine and improve the safety of medication.
[0142] As can be seen from Examples 1-6 and Application Examples 1-6, the pharmaceutical composition prepared by the present invention is resistant to strong acids, has strong penetrating ability and a long blood half-life, accelerates drug release in a GSH-triggered environment, enhances the anti-cancer effect of chemotherapy drugs, and reduces toxic side effects, making it an effective oral drug delivery method.
[0143] The applicant declares that the present invention is illustrated by the above embodiments to demonstrate a pharmaceutical composition, its preparation method, and its application. However, the present invention is not limited to the above embodiments, i.e., it does not mean that the present invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, and selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A pharmaceutical composition, characterized in that, The pharmaceutical composition includes a carrier and a drug loaded on the carrier, the carrier comprising a combination of a dialkylcysteine dipeptide and a lipid, the lipid being composed of a silicon-complexed lipid derivative and phospholipid polyethylene glycol, the dialkylcysteine dipeptide having a structure as shown in Formula 1-1: ; The silicon-based lipid derivative is N-[N-(3-triethoxysilane)-propylsuccinic acid]bishexadecan; The molar ratio of the phospholipid polyethylene glycol and the dialkylcysteine dipeptide is 1:(5-14). The molar ratio of the phospholipid polyethylene glycol and the silicon-based lipid derivative is 1:(5-14). The drug includes gemcitabine.
2. The pharmaceutical composition according to claim 1, characterized in that, The mass ratio of the drug to the carrier is 1:(0.05-0.35).
3. A method for preparing the pharmaceutical composition as described in claim 1 or 2, characterized in that, The preparation method includes: The drug, lipids, and dialkylcysteine dipeptide are mixed to obtain the drug composition.
4. The preparation method according to claim 3, characterized in that, The preparation method specifically includes: mixing a first solvent, a drug, a silicon-containing complex lipid derivative, phospholipid polyethylene glycol, and a dialkylcysteine dipeptide; removing the first solvent; adding a second solvent to reconstitute; centrifuging; adding a third solvent to reconstitute; and obtaining the drug composition.
5. The preparation method according to claim 3, characterized in that, The mixing temperature is 10-30 ℃.
6. The preparation method according to claim 3, characterized in that, The mixing time is 5-30 minutes.
7. The preparation method according to claim 4, characterized in that, The first solvent includes any one or a combination of at least two of methanol, ethanol, chloroform or ethyl acetate.
8. The preparation method according to claim 4, characterized in that, The concentration of the drug in the first solvent is 1-2 mg / mL.
9. The preparation method according to claim 4, characterized in that, The second solvent includes any one or a combination of at least two of water, phosphate buffer, or physiological saline.
10. The preparation method according to claim 4, characterized in that, The concentration of the drug in the second solvent is 0.01-1 mg / mL.
11. The preparation method according to claim 4, characterized in that, The reconstitution includes any one or a combination of at least two of stirring, vortexing, or sonication.
12. The preparation method according to claim 4, characterized in that, The third solvent includes any one or a combination of at least two of deionized water, phosphate buffer, or physiological saline.
13. The preparation method according to claim 4, characterized in that, The concentration of the drug in the third solvent is 0.01-10 mg / mL.
14. Use of a pharmaceutical composition as described in claim 1 or 2 in the preparation of an oral pharmaceutical formulation.
Citation Information
Patent Citations
Lipid carrier and method of preparing the same
CN1947702A
Nano-drug loading system with glutathione responsiveness, and preparation method and application thereof
CN110804178A
